Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Doug Meetmer who wrote (381)	10/28/1998 11:09:00 PM
From: Biomaven	Respond to of 717

Doug: Does anyone know what the potential market is for GD-Tx for brain mets? According to the latest release, "In the United States, about 170,000 patients receive radiation therapy each year for treatment of brain metastases." At $2,000 a treatment (my guess at a price for the multiple doses used because the raditaion is fractionated), that would be a potential market of $340m per year just for brain metastases. Are there any other radiation sensitizers out there avilable now? I don't believe there is anything currently available in the US. There are other potential candidates out there, but I believe most (maybe all) either don't work for hypoxic cells and/or need to be used for prolonged periods because their concentration mechanism relies on cell division. One comment on the results released today. They seem to have lumped together all the patients in the trial as being in the Gd-Tex group, even though the first 9 patients received Gd-Tex doses that were too small to be effective (it was a dose-escalation study), and had substantially worse outcomes than the later patients. If they had excluded these 9 patients, the results would have been even better. (The median survival in the low-dose group was only 66 days, making it likely that the sufficient-dose group had 12 month survival of 15/52 or 29%, more than twice the 14% survival for the case-matched controls.) Peter